Stockreport

Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the developm [Read more]